When the researchers compared those with only preconception exposure to GLP-1s and those who had been taking GLP-1s after conception, the aORs remained significant only for those exposed after conception. Less Preterm Birth but Other Complications More Likely.
Key takeaways: GLP-1 receptor agonist use before pregnancy was tied to lower risks for hypertensive disorders of pregnancy and gestational diabetes.
GLP-1 medications were developed as type 2 diabetes treatments, not weight loss drugs. Semaglutide and tirzepatide entered clinical use as glucose-regulating agents.
In the brain, GLP-1s reduce appetite and cravings (the fundamental mechanism of addictive disease). Alcohol use disorder (AUD) is the third-leading cause of preventable death in the United States, yet there are only three modestly effective drugs for treatment, the last one approved in 2006.
News about GLP-1 pregnancy. MedPage Today. Study Looks at GLP-1 Use in Pregnancy and Gestational Weight Gain.
Over the last few years GLP-1's for weight loss have exploded and it feels like everyone is on them. I talk to registered dietician nutritionist Melainie Rogers about how these medications work, the dangers with them and the impact they are having on recovery...
Shapeshifting market. Todays patients that initiate GLP-1 treatment particularly the treatments with explicit weight loss indications or strong clinical data for weight loss look less like the typical diabetes patients they used to resemble.
Furthermore, visual representations like the one above help us fully grasp the concept of Popular Preconceptions About Glp-1 Treatment.
In the summer of 2022, I decided to try taking Ozempic to lose weight. At the time, I was an early adopter. The media frenzy about GLP-1 agonists hadn't yet started.
In recent years, the topic of the GLP-1s, drugs such as Ozempic, Wegovy, Mounjaro, Zepound and others has taken the forefront of the discussion of the treatment of overweight and obesity. And understandably so, given that they represent the first true improvement on the issue.
